• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Paragonix reaches milestone of 2,000 organs preserved, transported for transplantation

Paragonix reaches milestone of 2,000 organs preserved, transported for transplantation

August 17, 2022 By Sean Whooley

Paragonix organ preservation transport
Paragonix’s organ preservation transport [Image from Paragonix]
Paragonix Technologies announced today that it has preserved more than 2,000 donor organs for transport and transplantation.

Cambridge, Massachusetts–based Paragonix designed its devices to combine clinically proven, stable, hypothermic preservation technology with an extensive clinical support network. There are digital tools for complete control over the process of organ tracking, monitoring and reporting.

“We are humbled and grateful to be part of transplant patients’ path to a new life while honoring the selfless gift of donor patients with our technology,” Paragonix CEO Dr. Lisa Anderson said in a news release. “Our portfolio of advanced organ preservation and tracking systems provides a safe and effective way for donor organs to be preserved, tracked, and transported to their destination.”

Paragonix has additional positive numbers

The company said that, along with its milestone of 2,000 preserved, transported and tracked donor organs, its research partners have enrolled 1,400 patients in the past three years from 22 transplant centers for the Guardian series of clinical registries.

Additionally, customers have downloaded more than 1,200 data reports on donor organ procurements. The Paragonix app has provided an estimated 800,000d data points related to donor organ transplants, and the company has provided in-person support in more than 800 donor organ procurements.

The company said that, in the second quarter of 2022, its Paragonix SherpaPak CTS helped preserve 27% of all donor hearts transplanted in the U.S.

Combined with the LUNGguard donor long preservation system, the company’s preservation devices played a role in 24% of all U.S. thoracic organ transplants in 2022.

Earlier this year, the company launched the LIVERguard system to offer access to advanced organ preservation to the abdominal market. The system represents an advance in the use of ice and off-the-shelf coolers that have been the standard of care in organ transplantation, Paragonix said. The company also recently announced that it expanded the adoption of LIVERguard to eight U.S. transplant centers.

Filed Under: Business/Financial News, Featured, News Well, Transplants Tagged With: Paragonix Technologies

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy